{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:10:19Z","timestamp":1733703019659,"version":"3.30.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,8]]},"DOI":"10.7759\/cureus.75338","type":"journal-article","created":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T23:54:26Z","timestamp":1733702066000},"source":"Crossref","is-referenced-by-count":0,"title":["Coexisting Thalassemia, Immune Thrombocytopenic Purpura, and Multiple Myeloma With Osteopenia: Complex Hematologic Case in an Adult Asian Male Patient"],"prefix":"10.7759","author":[{"given":"Javier B","family":"Chambi-Torres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohair","family":"Angly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Michel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21103538","article-title":"Hematological diseases and osteoporosis","volume":"21","author":"Gaudio A","year":"2020","unstructured":"Gaudio A, Xourafa A, Rapisarda R, Zanoli L, Signorelli SS, Castellino P. Hematological diseases and osteoporosis. Int J Mol Sci. 2020, 21:10.3390\/ijms21103538","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24681","article-title":"Hematologic malignancies in thalassemia: adding new cases to the repertoire","volume":"92","author":"Halawi R","year":"2017","unstructured":"Halawi R, Beydoun H, Cappellini MD, Ferla V, Taher A. Hematologic malignancies in thalassemia: adding new cases to the repertoire. Am J Hematol. 2017, 92:E68-70. 10.1002\/ajh.24681","journal-title":"Am J Hematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2020.1012","article-title":"Multiple myeloma with concurrent immune thrombocytopenic purpura","volume":"14","author":"Sarfraz H","year":"2020","unstructured":"Sarfraz H, Anand K, Liu S, Shah S. Multiple myeloma with concurrent immune thrombocytopenic purpura. Ecancermedicalscience. 2020, 14:1012. 10.3332\/ecancer.2020.1012","journal-title":"Ecancermedicalscience"},{"key":"ref4","article-title":"Thalassemia","author":"Bajwa H","year":"2024","unstructured":"Bajwa H, Basit H. Thalassemia. StatPearls. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref5","article-title":"Multiple myeloma","author":"Albagoush SA","year":"2024","unstructured":"Albagoush SA, Shumway C, Azevedo AM. Multiple myeloma. StatPearls. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref6","article-title":"ITP-immune thrombocytopenic purpura","author":"Justiz Vaillant AA","year":"2024","unstructured":"Justiz Vaillant AA, Gupta N. ITP-immune thrombocytopenic purpura. StatPearls. StatPearls Publishing, Trasure Island, FL; 2024."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2257.2000.00125.x","article-title":"Multiple myeloma and immune thrombocytopenia","volume":"22","author":"Gupta V","year":"2000","unstructured":"Gupta V, Hegde UM, Parameswaran R, Newland AC. Multiple myeloma and immune thrombocytopenia. Clin Lab Haematol. 2000, 22:239-42. 10.1046\/j.1365-2257.2000.00125.x","journal-title":"Clin Lab Haematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020455","article-title":"Exon-4 mutations in KRAS affect MEK\/ERK and PI3K\/AKT signaling in human multiple myeloma cell lines","volume":"12","author":"Wei\u00dfbach S","year":"2020","unstructured":"Wei\u00dfbach S, Heredia-Guerrero SC, Barnsteiner S, et al.. Exon-4 mutations in KRAS affect MEK\/ERK and PI3K\/AKT signaling in human multiple myeloma cell lines. Cancers (Basel). 2020, 12:10.3390\/cancers12020455","journal-title":"Cancers (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3208","article-title":"Effect of MAPK activation via mutations in NRAS, KRAS and BRAF on clinical outcome in newly diagnosed multiple myeloma","volume":"41","author":"Perroud C","year":"2023","unstructured":"Perroud C, Thurian D, Andres M, et al.. Effect of MAPK activation via mutations in NRAS, KRAS and BRAF on clinical outcome in newly diagnosed multiple myeloma. Hematol Oncol. 2023, 41:912-21. 10.1002\/hon.3208","journal-title":"Hematol Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-23-0208","article-title":"Multiple myeloma risk and outcomes are associated with pathogenic germline variants in DNA repair genes","volume":"5","author":"Thibaud S","year":"2024","unstructured":"Thibaud S, Subaran RL, Newman S, et al.. Multiple myeloma risk and outcomes are associated with pathogenic germline variants in DNA repair genes. Blood Cancer Discov. 2024, 5:428-41. 10.1158\/2643-3230.BCD-23-0208","journal-title":"Blood Cancer Discov"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0061","article-title":"Multiple myeloma, version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Kumar SK","year":"2023","unstructured":"Kumar SK, Callander NS, Adekola K, et al.. Multiple myeloma, version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023, 21:1281-301. 10.6004\/jnccn.2023.0061","journal-title":"J Natl Compr Canc Netw"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.11406\/rinketsu.57.630","article-title":"Multiple myeloma developing in a patient with immune thrombocytopenia (Article in Japanese)","volume":"57","author":"Itoh T","year":"2016","unstructured":"Itoh T. Multiple myeloma developing in a patient with immune thrombocytopenia (Article in Japanese). Rinsho Ketsueki. 2016, 57:630-3. 10.11406\/rinketsu.57.630","journal-title":"Rinsho Ketsueki"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092544","article-title":"Latest development in multiple myeloma","volume":"12","author":"Imai Y","year":"2020","unstructured":"Imai Y. Latest development in multiple myeloma. Cancers (Basel). 2020, 12:10.3390\/cancers12092544","journal-title":"Cancers (Basel)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2014.2726","article-title":"PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA\/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226\/R","volume":"46","author":"Xiong T","year":"2015","unstructured":"Xiong T, Wei H, Chen X, Xiao H. PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA\/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226\/R. Int J Oncol. 2015, 46:223-32. 10.3892\/ijo.2014.2726","journal-title":"Int J Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/311415-coexisting-thalassemia-immune-thrombocytopenic-purpura-and-multiple-myeloma-with-osteopenia-complex-hematologic-case-in-an-adult-asian-male-patient","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T23:54:28Z","timestamp":1733702068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/311415-coexisting-thalassemia-immune-thrombocytopenic-purpura-and-multiple-myeloma-with-osteopenia-complex-hematologic-case-in-an-adult-asian-male-patient"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,8]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.75338","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,8]]}}}